Beta-catenin and b-cell lymphoma 9 (BCL9) inhibitors

A compound having Formula I-B:

• wherein A is selected from N or —CR8, where R8 is hydrogen, halogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
• wherein Z is selected from N or —CR2a, wherein R2a is hydrogen, halogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
• wherein L1 is optionally present, and when present, is O, S, NH, or CR12aR12b, wherein R12a and R12b are independently selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
• wherein L2 is optionally present, and when present, is O, S, C1-C3 alkyl, or —(NR17a)—, wherein R17a is selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
• wherein each of R1a and R1b is independently hydrogen, halogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
• wherein each of R2b and R2c is independently hydrogen, halogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
• wherein R3 is Cy3 or Ar1;
• wherein Cy3 is a C3-C8 cycloalkyl or a C2-C7 heterocycloalkyl and Ar is selected from aryl and heteroaryl, wherein each of Cy3 and Ar1, when present, is substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, R10NHCO—(R10 substituted carbamoyl group), wherein R10 is selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl, or R11CONH—(R11 substituted amido group),
• wherein R4 is selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
• wherein R4 is hydrogen, halogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, or R15CONH—, wherein R15 is selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl, or Ar2, wherein Ar2 is selected from aryl, heteroaryl, and wherein Ar2 is substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl;
• wherein each occurrence of R5 is independently selected from hydrogen, C1-C8alkyl, C1-C8 monohaloalkyl, C1-C3 polyhaloalkyl, R14CONH—, wherein R14 is selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
• wherein R6 is C1-C6 aminoalkyl, C1-C6 hydroxyalkyl, or Cy1;
• and wherein Cy1 is an amino C3-C8 cycloalkyl, a hydroxy C3-C8 cycloalkyl, or a C2-C7 heterocycloalkyl comprising at least one oxygen or nitrogen atom;
• and wherein Cy1 is substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl;
• wherein R7 is Cy5, NR12aR12b-Cy5, NR12aR12b—C1-C6 unsubstituted alkyl-Cy5, C1-C6 unsubstituted alkyl-NH—(C═O)—;
• C1-C6 unsubstituted alkyl-(C═O)—NH—;
• or C1-C6 unsubstituted alkyl-NHCH2-Cy5—,
• amino C1-C6 substituted or unsubstituted alkyl carbonyl, hydroxyl C1-C6 substituted or unsubstituted alkyl carbonyl, amino C1-C6 substituted or unsubstituted alkyl, hydroxyl C1-C6 substituted or unsubstituted alkyl,
• wherein Cy5 is selected from a C2-C7 heterocycloalkyl or heteroaryl comprising at least one oxygen or nitrogen atom, amino C3-C8 cycloalkyl, a hydroxy C3-C8 cycloalkyl, a C3-C7 oxoheterocycloalkyl comprising at least one oxygen or nitrogen atom, an amino C3-C8 oxocycloalkyl, or a hydroxy C3-C8 oxocycloalkyl, and wherein Cy5 is substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, C1-C4 alkyl, C1-C4 monohaloalkyl, or C1-C4 polyhaloalkyl, and
• m is 0, 1, 2, or 3,
• or a pharmaceutically acceptable salt, ester, or prodrug thereof.